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Abstract
Despite substantial advancement in the understanding and treatment of chronic lymphocytic leukemia 
(CLL), a standard curative approach does not exist. The choice of treatment is generally based on the 
existence of biological and genetic factors associated with the prediction of prognosis, individual response 
to therapy, and duration of remission. About 20% of patients that require treatment have an aggressive 
disease course and die within a few years, despite early initiation of intensive therapy (poor-risk CLL). 
Poor-risk CLL can be predicted by the presence of genomic markers, and the quality and duration of 
response  to  purine-analogue-based  treatment.  Within  this  patient  subgroup  alternative  treatment 
approaches such as alemtuzumab or new substances such as flavopiridol or IMiDs® should be considered. 
To date, the only treatment bearing curative potential is allogeneic stem cell transplantation; in contrast 
to conventional immunochemotherapy, it can provide long-term disease control, even in patients with del 
17p or other unfavorable biological and clinical risk factors. The aim of this review was to outline the cur-
rent strategies for the diagnosis and management of CLL, with a focus on high-risk CLL.
(Turk J Hematol 2011; 28: 86-96)
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Özet
Kronik lenfositik löseminin (KLL) tanı ve tedavisine yönelik önemli gelişmelere karşın, şifa sağlayıcı 
(küratif) standart bir yaklaşım henüz bulunmamaktadır. Tedavi seçimi genellikle prognozu öngören 
biyolojik ve genetik faktörlerin varlığına, tedaviye alınan bireysel yanıt ve iyileşme (remisyon) süresine 
dayanır. Tedavi edilmesi gereken hastaların yaklaşık %20’si hızla ilerleyen bir klinik gidiş gösterirler 
ve yoğun tedaviye erkenden başlanmasına karşın birkaç yıl içerisinde yaşamlarını yitirirler (yüksek 
riskli KLL). Yüksek riskli KLL olasılığı, genomik belirteçler yanında  purin-analogu temelli tedaviye 
alınan yanıtın niteliği ve süresiyle önceden kestirilebilir. Bu hasta altgrubunda, alemtuzumab gibi 
alternatif tedavi yaklaşımları ya da flavopiridol ve IMiD® grubu gibi yeni ilaçlar göz önüne alınmalıdır. 
Günümüzde bu hastalarda şifa sağlayıcı potansiyele sahip tek tedavi seçeneği allogeneik kök hücre 
naklidir. Bu yöntemle, geleneksel immünokemoterapinin aksine, del 17p veya diğer olumsuz biyolojik 
ve klinik risk faktörlerine sahip hastalarda bile hastalığın uzun süreli denetimi sağlanabilir. Bu derle-
yici incelemede, yüksek riskli KLL’ye odaklanarak KLL tanı ve tedavisine ilişkin güncel stratejilerin 
özetlenmesi amaçlanmıştır. (Turk J Hematol 2011; 28: 86-96)
Anahtar kelimeler: KLL, genetik, yüksek risk, tedavi, allogeneik kök hücre transplantasyonu
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Chronic lymphocytic leukemia (CLL) is one of 
the most common lymphoid malignancies, account-
ing for more than 10% of all lymphoid neoplasms, 
and is the most common adult leukemia in Western 
countries,  with  an  age-adjusted  annual  incidence 
rate of about 4 cases per 100.000 men and women 
[1,2]. While the median age at diagnosis is over 70 
years, approximately 30% of patients are diagnosed 
at  an  age  of  ≤65  years.  The  disease  has  a  slight 
male  predominance  (male:female  ratio:  1.5-2:1). 
Clinical  features  are  highly  variable,  and  most 
patients  are  asymptomatic.  As  the  disease  pro-
ceeds, fatigue, splenomegaly, hepatomegaly, lymph-
adenopathy, and extranodal infiltrates are observed. 
Another hallmark is immune suppression and defi-
ciency,  including  hypogammaglobulinemia,  auto-
immune  phenomena,  and  impaired  response  to 
vaccination, which is further exacerbated by thera-
py-related immunosuppression [3].
Diagnosis
To unify the criteria for diagnosis and response 
assessment  a  working  group  sponsored  by  the 
National Cancer Institute first published guidelines 
for the design and conduct of clinical trials on CLL 
in  1988  [4].  Following  an  update  in  1996,  the 
International Workshop on CLL (iwCLL) revised the 
guidelines, taking into account the substantial prog-
ress that had been made in the understanding and 
treatment of the disease [5]. The recommendations 
for diagnosis and treatment discussed in this review 
are based on the iwCLL criteria. 
The diagnosis of CLL requires the presence of cells 
with  a  CLL-specific  immunophenotype,  along  with 
≥5.000 B-lymphocytes µL–1 in peripheral blood [5]. 
The presence of CLL cells with a lower B-lymphocyte 
count in the absence of lymphadenopathy, organo-
megaly, or cytopenia is now defined as monoclonal 
B-lymphocytosis (MBL) [6]. The presence of lymph-
adenopathy  or  splenomegaly,  and  a  B-lymphocyte 
count ≤5.000 µL–1 is defined as small lymphocytic 
lymphoma (SLL). More than 55% prolymphocytes in 
the blood suggests a diagnosis of B-cell prolympho-
cytic leukemia (B-PLL) [7]. 
Flow cytometry is essential for determining the 
clonality of B-lymphocytes and the following charac-
teristic CLL-cell-surface phenotypes: the presence of 
CD19,  CD5,  CD23  and  CD43,  weak  expression  of 
CD20 and CD79b, and kappa or lambda immuno-
globulin light chains [8,9]. The expression of CD38 is 
variable, but has prognostic significance and should 
therefore  be  evaluated  [10,11].  Flow  cytometry  is 
also indispensable for differentiating CLL from other 
lymphoproliferative diseases, such as hairy cell leu-
kemia, leukemic manifestations of mantle cell lym-
phoma, marginal zone lymphoma, splenic marginal 
zone lymphoma, and follicular lymphoma. 
Bone  marrow  investigation  is  generally  not 
required  for  the  diagnosis  of  CLL,  especially  in 
patients without cytopenia and those not requiring 
treatment. Bone marrow aspiration and biopsy may 
be indicated, however, when treatment is required, 
as the extent and pattern (diffuse vs. non-diffuse) of 
bone marrow infiltration can provide valuable infor-
mation on tumor burden and factors that may con-
tribute to cytopenia. Post-treatment bone marrow 
investigation is recommended in patients with per-
sisting  cytopenia  of  unknown  origin.  In  SLL  the 
diagnosis  should  be  verified  via  histopathological 
evaluation of a lymph node biopsy specimen. 
Clinical Staging and Prognosis
As the clinical course of CLL varies widely, stag-
ing systems have been developed to stratify patients 
into  different  risks  groups  for  predicting  survival. 
The 2 most commonly used are the Rai and Binet 
staging  systems  [12,13].  Both  systems  consist  of 
parameters that are obtained via clinical examina-
tion and standard laboratory tests, and are therefore 
easy to obtain. Ultrasound and computed tomogra-
phy  are  not  required,  although  they  increase  the 
accuracy  of  the  assessment  of  intra-abdominal 
lymph  nodes  and  organomegaly.  Table  1  outlines 
the  parameters  that  define  the  clinical  stages.  To 
account for extreme heterogeneities observed with-
in each risk group, Wierda et al. proposed a new 
prognostic  index  for  previously  untreated  CLL 
patients for predicting overall survival (OS) [14]: in 
the  Rai  staging  system  age,  absolute  lymphocyte 
count, gender, b2-microglobulin concentration, and 
the number of involved lymph nodes were indepen-
dently associated with OS. This index was validated 
in an independent patient cohort by a Mayo Clinic 
study [15]. A recent observational database study by 
GIMEMA  (Gruppo  Italiano  Malattie  EMatologiche 
dell´Adulto) also confirmed the utility of the index 
for predicting time to first treatment [16]. 
Indications for Treatment
As  there  is  no  standard  curative  approach  for 
CLL, the decision to begin treatment is based on the 
development  of  symptoms  and  disease  activity. 
Newly diagnosed asymptomatic patients should be 
monitored without therapy, as there is no document-
ed benefit from early anti-leukemic treatment [5]. 
Patients with symptomatic, advanced, or rapidly pro-
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Definitions of disease activity are listed in Table 2. 
The decision to begin second-line treatment gener-
ally follows the same guidelines. 
Factors Guiding the Choice of Treatment
Physical fitness and comorbidity
Once treatment is indicated, each patient’s indi-
vidual physical condition and degree of co-morbidity 
should  be  evaluated.  In  completely  independent 
patients with no comorbidity and otherwise normal 
life expectancy (go-go patients) aggressive chemo-
therapy aimed at the prolongation of survival is rec-
ommended. The goal in patients with some co-mor-
bidity, impaired organ function, and reduced perfor-
mance status (slow-go patients) is to achieve disease 
remission  via  a  less  aggressive  approach.  Patients 
that  are  severely  handicapped  and  have  high  co-
morbidity (no-go patients) might often fare best with 
supportive palliative care only. Physical fitness can be 
determined empirically or by using the cumulative 
illness rating scale (CIRS) [17]. 
Biological prognostic factors
Substantial progress has been made in the identifi-
cation of biological and genetic factors that are strong-
ly associated with the prediction of prognosis, indi-
vidual response to therapy, and duration of remission. 
Several studies reported that elevated serum thymi-
dine  kinase  (sTK),  b2-microglobulin,  and  soluble 
CD23  may  predict  OS  or  progression-free  survival 
(PFS) [18-21]. Using fluorescence in-situ hybridization 
(FISH)  cytogenetic  aberrations  can  be  identified  in 
more than 80% of CLL patients [22]. The most com-
mon chromosomal aberrations are del 13q, del 11q, 
trisomy 12, del 17p, and del 6q, with 13q deletion indi-
cating the best prognosis with a median survival of 
>10 years and 17p deletion indicating a particularly 
poor prognosis with a median survival of <3 years, 
even with modern fludarabine/rituximab-based front-
line treatments. 
Somatic  mutations  in  the  gene  encoding  the   
variable region of the heavy chain of immunoglobu-
lins  (IGHV)  occur  in  approximately  50%  of  CLL 
patients  [23].  Patients  lacking  a  mutation  in  this 
region (unmutated IGHV) tend to have a more pro-
gressive and advanced form of CLL than patients with 
mutated IGHV. This was first shown retrospectively in 
patients treated in the pre-purine-analogue era, but 
has  been  confirmed  in  prospective  studies  using 
fludarabine combination regimens [11,24]. As testing 
for IGHV mutation status is complex and expensive, 
ZAP-70 expression was reported to correlate with the 
expression of unmutated IGHV [11,24,25]; however, 
the  association  between  ZAP-70  and  IGHV  is  not 
definitive.  According  to  the  iwCLL  guidelines,  with 
the exception of del 17p FISH, these tests should not 
Table 1. Rai and Binet clinical staging
Risk group  Rai  Binet
Low  0: lymphocytosis with CLL cells in PB and/or   A: Hb ≥100 g L-1 (10 g dL-1), platelet count
  BM, lymphoid cells >30%  ≥100×109 L-1, and up to 2 lymph node areas involved*
Intermediate  1/2: Lymphocytosis, enlarged lymph nodes at any   B: Hb ≥100 g L-1 (10 g dL-1), platelet count
  site, splenomegaly and/ or hepatomegaly  ≥100x109 L-1, and organomegaly greater than that 
    defined for stage A (i.e. ≥3 areas of nodal or organ 
    enlargement)
High  3/4: Disease-related anemia (Hb <110 g L-1   C: Hb <100 g L–1 (10 g dL–1) and/or a platelet count
  [11 g dL-1]) or thrombocytopenia (plt <100x109 L-1)  <100x109 L–1, irrespective of organomegaly
*Areas of involvement considered for staging
1. Head and neck, including the Waldeyer ring (this counts as 1 area, even if >1 group of nodes is enlarged)
2. Axillae (involvement of both axillae counts as 1 area)
3. Groins, including superficial femorals (involvement of both groins counts as 1 area)
4. Palpable spleen
5. Palpable liver
Table 2. Definitions of disease activity
At least 1 of the following:
1.  Evidence  of  progressive  marrow  failure:  anemia  and/or 
thrombocytopenia
2.  Massive (i.e. ≥6 cm below the left costal margin) or progres-
sive or symptomatic splenomegaly
3.  Massive nodes (i.e. ≥10 cm in diameter), or progressive or 
symptomatic lymphadenopathy
4.  Progressive  lymphocytosis  with  an  increase  >50%  over  a 
2-month  period,  or  lymphocyte  doubling  time  (LDT)  <6 
months. 
5.  Autoimmune anemia and/or thrombocytopenia
6.  Constitutional symptoms: unintentional weight loss, signifi-
cant fatigue, fevers, night sweats
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sion-making; however, it is essential to consider the 
existence and importance of these tests at the time 
of first diagnosis. 
First-line Treatment
Go-go patients without del 17p
Following traditional treatment approaches con-
sisting  of  alkylating  agents  (mostly  cyclophospha-
mide or chlorambucil) with or without nucleoside 
analogue-based  substances,  the  combination  of 
monoclonal  antibodies  with  chemotherapy 
increased the complete response (CR) rate from 4% 
[26] to 70% [27-30]. A large phase III trial that ran-
domly assigned patients to 6 courses of fludarabine 
and  cyclophosphamide  (FC),  or  rituximab-FC 
(R-FC) was conducted by the German CLL Study 
Group (GCLLSG) (CLL8 trial). At 3 years post treat-
ment,  65%  of  the  patients  in  the  chemoimmuno-
therapy group were progression free, compared to 
45%  in  the  chemotherapy  group  (HR:.56;  95%   
CI: .46-.69; p<0.0001) [31]. Additionally, 3-year OS 
was significantly longer in the R-FC group (87% vs. 
83%, p=0.01), and R-FC treatment was associated 
with a significantly higher complete remission (CR) 
rate and longer duration of response. Although R-FC 
was more frequently associated with grade 3 and 4 
neutropenia  and  leucopenia,  it  is  now  considered 
the gold standard treatment for physically fit patients 
without 17p deletion. In another GCLLSG phase II 
trial previously untreated patients received 6 cycles 
of bendamustine (90 mg m-2 on d 1 and 2) with ritux-
imab (375 mg m-2 for the first cycle and 500 mg m-2 
for  subsequent  cycles,  repeated  every  28  d)  (R-B 
regimen) [32]. The overall response (OR) rate was 
91%, including 33% of patients with CR. Hematopoietic 
and  overall  toxicity  of  R-B  was  modest.  After  18 
months 76% of the patients were still in remission, 
while  median  progression-free  survival  (PFS)  had 
not been reached. R-B can therefore be considered 
safe and effective. The GCLLSG is currently conduct-
ing  a  randomized  phase  III  trial  to  make  a  direct 
comparison of R-B and R-FC. 
Variations of the R-FC regimen have been tested 
extensively. For example, Bosch et al. conducted a 
phase  II  trial  with  29  previously  untreated  CLL 
patients  receiving  rituximab  plus  FCM  (mitoxan-
trone), followed by rituximab maintenance every 3 
months for up to 2 years [33]. The OR, MRD- (mini-
mal  residual  disease)  negative  CR,  MRD-positive 
CR, and PR rates were 93%, 46%, 36%, and 11%, 
respectively,  proving  the  efficacy  of  the  regimen. 
Another approach was substitution of fludarabine 
by pentostatine (R-PC). A phase III randomized trial 
of  R-FC  versus  R-PC  in  previously  untreated  and 
minimally treated CLL patients showed that there 
weren’t  any  statistical  differences  between  OS, 
response, or infection rates [34]. 
The role of autologous stem cell transplantation
Autologous hematopoietic stem cell transplanta-
tion  (autoHSCT)  is  considered  an  attractive  treat-
ment  alternative  for  a  select  group  of  patients. 
Pioneers  in  the  field  of  autoHSCT  for  CLL  are 
Gribben et al. from the Dana Faber Cancr Center 
[35].  An  update  published  in  2005  showed  that 
relapses continued to occur after 10 years of follow-
up, translating into a 6-year PFS of 30% and a 6-year 
OS of 58% [36]. In the MRC pilot study, a large mul-
ticenter phase II trial on autoHSCT as a coponent of 
first-line CLL treatment, the 5-year OS and PFS rates 
were 78% and 52%, respectively [37]. An update of 
the GCLLSG CLL3 study, which had a similar design, 
reported a median OS of 10.5 years and a median 
PFS of 6.8 years after early autoHSCT [38]. The first, 
and  to  date,  only  phase  III  randomized  trial  was 
conducted by the EBMT; 39 patients with CR after 
first- or second-line treatment were randomized to 
consolidating  autoHSCT  or  observation.  Median 
event-free survival (EFS) was 24.4 months (range: 
16.7-32 months) in the observation group and 51.2 
months (range: 39.8-62.5 months) in the autoHSCT 
group,  indicating  a  5-year  EFS  of  24%  and  42%, 
respectively.  While  autoHSCT  almost  doubled 
event-free survival (EFS) and time to retreatment, 
there wasn’t a significant difference in OS (5-year 
OS was 84% and 86%, respectively). In addition, sev-
eral studies indicate that autoHSCT fails to achieve 
durable MRD negativity [40,41], which means that 
autoHSCT cannot be considered as a curative treat-
ment in CLL. Moreover, long-term follow-up obser-
vations have raised concerns about the increased 
incidence  of  therapy-related  myeloid  neoplasms 
(MDS  and  AML)  following  autoHSCT.  In  the  Dana 
Faber and MRC series the 5- and 8-year incidence of 
therapy-related myeloid neoplasms was 12% [36,42], 
versus a 10-year incidence rate of 8% in the CLL3 
trial [38]. Due to these limitations, autoHSCT cannot 
be recommended as a standard approach in CLL 
and should only be used in clinical trials. 
Go-go patients with del 17p 
As patients carrying del 17p have a high risk of 
very poor outcome with fludarabine-based regimens 
that  include  bendamustine,  alternative  treatment 
Mc Clanahan et al.
Treatment of chronic lymphocytic leukemia Turk J Hematol 2011; 28: 86-96 89approaches should be considered. It is well known 
that alemtuzumab has a similar affect in del 17p and 
non-del 17p CLL patients [43]. In the ongoing pro-
spective GCLLSG CLL2o study patients with del 17p 
or refractoriness to fludarabine received subcutane-
ous alemtuzumab combined with oral dexametha-
sone,  followed  by  alemtuzumab  maintenance  or 
allogeneic  hematopoietic  stem  cell  transplantation 
(alloHSCT). As of September 2010, 80 patients were 
enrolled in the protocol, of which 31 without prior 
therapy had del 17p and 17 that relapsed had del 17p 
[44]. OR and CR were 100% and 23%, respectively, in 
the del 17p first-line group, which are considerably 
higher than those in the CLL8 study F-CR group (71% 
and 5%, respectively). Adverse events were hemato-
toxicity and grade 3/4 cytomegaly virus (CMV) infec-
tion (16%); however, the response duration following 
alemtuzumab is usually limited, making the search 
for  effective  first-line  consolidation  mandatory.  To 
date, the only treatment with the potential for long-
term disease control in the del 17p patient subgroup 
is alloHSCT, which will be discussed in detail below.
Slow-go patients with and without del 17p
Patients with relevant comorbidity may be offered 
chlorambucil,  bendamustine,  or  a  dose-reduced 
fludarabine-containing  regimen,  with  or  without 
rituximab, depending on the fragility of the patient 
[45,46].  Alemtuzumab  can  also  be  considered  in 
appropriate patients (i.e. those with del 17p). The 
GCLLSG  is  currently  conducting  an  open-label 
3-arm  randomized  phase  III  trial  to  compare  the 
efficacy  and  safety  of  the  new  monoclonal  CD20 
antibody  RO5072759  (GA101)  plus  chlorambucil 
(GClb)  to  those  of  rituximab  plus  chlorambucil 
(RClb)  or  chlorambucil  only  (Clb)  in  previously 
untreated patients with comorbidity. 
Second-line Treatment
For selecting the appropriate indication and regi-
men  for  salvage  treatment,  the  same  criteria  for 
first-line therapy primarily apply; start only if symp-
toms or rapid lymphoproliferation are present, and 
consider comorbidity and the presence of del 17p. 
In addition, an important factor guiding the choice 
of salvage treatment is the quality and duration of 
response  to  the  previous  treatment  line;  patients 
that  relapse  >12  months  after  purine  analogue 
monotherapy or 24 months after completion of a 
modern combination treatment might benefit from 
repetition or modest escalation of the previous regi-
men, e.g. R-FC after F or FC, and R-B after R-FC. 
Before starting second-line treatment reassessment 
of  17p  status  is  highly  recommended  to  avoid 
unnecessary exposure to ineffective drugs in cases 
of  clonal  evolution.  In  contrast,  all  patients  that 
relapse sooner must be regarded as having poor-
risk CLL and treated accordingly. 
Definition of Poor-Risk CLL
About 20% of patients with CLL that require treat-
ment have an aggressive course and die within a 
few  years  of  diagnosis,  despite  early  initiation  of 
intensive  therapy.  The  hallmark  of  this  so  called 
poor-risk CLL is pre-existent or rapid development 
of resistance to the current standard combination 
regimens. Poor-risk CLL can be partially predicted 
by the presence of defined genomic markers.
Molecular markers
As  outlined  above,  the  existence  of  del  17p  is 
associated with poor prognosis [22]. Patients with 
17p deletion are often resistant to standard chemo-
therapy regimens. Following initial results of retro-
spective analyses [47], the adverse impact of del 17p 
was confirmed by several prospective phase III clini-
cal trials using purine-analogue-based therapy. The 
LRF CLL4 trial that included 777 CLL patients that 
required  treatment  reported  that  patients  with  del 
17p had significantly poorer response to fludarabine-
based treatment and shorter PFS [28]. In a Spanish 
trial del 17p was associated with a significantly lower 
CR rate [33], and in the GCLLSG CLL4 (F vs. FC) and 
CLL8 trials (FC vs. FCR) del 17p was associated with 
dramatically lower CR, OR, OS, and PFS [31]. 
Recent  data  suggest  that  the  vast  majority  of 
patients with del 17p had mutations of the remaining 
allele of the TP53 gene located in the deleted region 
of 17p [48]. Whereas TP53 mutations in general led to 
significantly shorter survival (p=0.002), survival was 
equally poor in patients with TP53 mutation only (5.5 
months), TP53 mutation plus del 17p (7.6 months), 
and del 17p only (5.4 months). In a recent analysis of 
the GCLLSG CLL4 trial (F vs. FC) TP53 mutation was 
observed in 8.5% of the patients, of which 4.5% did 
not have del 17p [49]. None of the patients with TP53 
mutation achieved CR, and median PFS and OS were 
significantly shorter in the group with TP53 mutation 
(p<0.001). As the outcome of patients with del 17p 
and/or  TP53  mutation-both  individually  and  com-
bined-was very poor, it was recently proposed that 
these patients be considered as ultra-high risk [50]. 
In 2010 Oscier et al. published a comprehensive 
report on the prognostic significance of age, gender, 
and  biomarkers  in  the  prediction  of  treatment 
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randomized British CLL4 trial [51]. Using the factors 
identified  as  independent  predictors  for  PFS,  they 
subdivided CLL4 patients into 3 risk groups: 6% with 
known TP53 loss >10% were considered poor risk 
and 72% without TP53 loss and at least 1 of the fol-
lowing factors-unmutated IGHV, IGHV3-21 usage, 11q 
deletion, and/ or b-2 microglobulin >4 m L–1-were 
considered intermediate risk. In all, 22% of patients 
were considered good risk, defined as none of the 
above  factors  and  mutated  IGHV.  The  5-year  PFS 
rates  in  these  3  groups  were  0%,  12%,  and  34%, 
respectively, and the corresponding 5-year OS rates 
were  9%,  53%  and  79%,  respectively,  which  con-
firmed the poor outcome of patients with del 17p and 
the prognostic impact of unmutated IGHV, b2-micro-
globulin, and 11q deletion. As this is a novel approach 
to risk stratification in CLL, it needs to be validated in 
patient  cohorts  treated  with  newer  combination 
therapies, including monoclonal antibodies. 
Response to treatment and duration of remission 
Independent of the presence of genomic poor-risk 
markers, the overriding predictor of poor-risk dis-
ease  is  the  response  to  purine-analogue-based 
treatment. According to the iwCLL guidelines, every 
clinical response that is not CR or PR (e.g. stable 
disease,  non-response,  or  progressive  disease) 
should be rated as a treatment failure. Refractory 
disease is defined as treatment failure or disease 
progression within 6 months of the completion of 
the last antileukemic treatment. Early data from the 
M.D. Anderson Cancer Center on 174 patients with 
progressive or advanced CLL that received first-line 
therapy with fludarabine or fludarabine combined 
with prednisone showed that patients that did not 
achieve a clinical response had significantly shorter 
OS  [52].  Patients  with  residual  disease  or  non-
response  after  fludarabine  combined  with  cyclo-
phosphamide and rituximab (R-FC) also had signifi-
cantly reduced OS [30]. 
Median survival was also significantly reduced in 
patients that initially responded to R-FC, but then 
relapsed within 36 months, as compared to those 
that  relapsed  ≥36  months  after  R-FC  treatment 
(p<0.0001)  [53].  In  an  analysis  of  the  CLL8  trial 
R-FC patients with PFS of 12-24 months (n=43) had 
a median post-relapse OS of <40 months. Outcomes 
for  relapsing  patients  treated  with  FC  within  the 
same time interval were even worse [54].
The poor-risk associated with resistant disease is 
reflected  in  both  the  iwCLL  guidelines  and  the 
EBMT  (European  Group  for  Blood  and  Marrow 
Transplantation) transplant consensus. According to 
iwCLL, patients with resistant disease (defined as a 
short time to progression after the first treatment) 
and/or  leukemia  cells  with  del  17p  should  be 
offered  alternative  treatment  approaches  such  as 
alloHSCT.  According  to  the  EBMT  consensus, 
patients with non-response or early relapse (within 
12 months) after purine analogue treatment relapse 
within  24  months  of  having  achieved  a  response 
with  purine-analogue-based  combination  therapy, 
or autologous transplantation and TP53 abnormali-
ties requiring treatment are potential candidates for 
alloHSCT [55]. 
Treatment of Poor-Risk CLL
As outlined in detail above, stable disease, non-
response,  progressive  disease,  and  refractory  dis-
ease  are  predictors  of  poor  survival,  and  such 
patients should be considered high-risk, regardless 
of pre-existing biomarkers. This means that patients 
that have not been considered for alemtuzumab or 
alloHSCT pre-treatment based on their cytogenetic 
risk  profile  are  candidates  for  a  more  intensive 
approach  based  on  their  inadequate  response  to 
first-line treatment. Most importantly, it is crucial to 
change the treatment components used in the ini-
tial  failed  approach.  There  are  several  treatment 
options,  including  alemtuzumab,  ofatumumab, 
experimental drugs, and alloHSCT.
The phase II GCLLSG CLL2H trial evaluated the 
safety and efficacy of subcutaneous alemtuzumab in 
patients with fludarabine-refractory CLL, and report-
ed that OR was 34% (4% CR and 30% PR), median 
PFS  was  7.7  months,  and  median  OS  was  19.1 
months  [56].  Efficacy  did  not  vary  significantly 
between genetic subgroups, indicating that alemtu-
zumab treatment could overcome the adverse prog-
nostic impact of IGHV mutation status, TP53 muta-
tion, and genomic aberrations. The potential benefit 
of alemtuzumab in combination with chemotherapy 
was first observed in 6 patients by Kennedy et al. 
[57]; their findings were confirmed by a phase II trial 
on relapsed or refractory CLL, which reported an OR 
of 83%, including 11 patients with CR, and resolution 
of disease in all affected sites [58]. 
In the ongoing GCLLSG CLL2o trial on the combi-
nation of alemtuzumab and high-dose dexametha-
sone,  31  of  the  80  patient  enrolled  to  date  were 
fludarabine-resistant; their OR rate was 47%, none 
achieved  CR,  and  12-month  OS  was  54%  [44].  A 
recently  published  interim  analysis  of  an  interna-
tional phase II study on the efficacy of the human 
monoclonal  CD20  antibody  ofatumumab  in  138 
patients  that  were  fludarabine-  and  alemtuzumab-
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and OS were 5.7 and 13.7 months, respectively, indi-
cating that ofatumumab might be a promising treat-
ment option for fludarabine-refractory patients with 
poor-prognosis  CLL  [59].  Alternative  treatment 
approaches using new substances, such as flavopiri-
dol or IMiDs®, are currently being tested in clinical 
trials, and some patients might be eligible for inclu-
sion in phase I or II clinical studies; however, none of 
the current or novel approaches has the potential for 
long-term disease control, highlighting the need for 
effective consolidation once remission is achieved.
The role of Allogeneic Stem Cell Transplantation
On the basis of its capacity to induce graft-ver-
sus-leukemia (GVL) effects [60], alloHSCT has been 
shown  to  provide  long-term  disease  control  in 
selected CLL patients [36,61-68]. Key outcome data 
from selected prospective clinical trials on reduced-
intensity  conditioning  (RIC)  are  summarized  in 
Table  3.  To  elucidate  the  effect  of  alloHSCT  in 
patients with del 17p, the EBMT performed a retro-
spective database analysis in which 44 patients with 
del 17p that received alloHSCT were identified [69]. 
After a median post-alloHSCT observation time of 
39 months, 19 patients were still alive. Three-year 
OS and PFS rates were 44% and 37%, respectively, 
and the cumulative incidence of disease progres-
sion at 4 years was 34%. During 4 years of follow-up 
no late relapses occurred in 9 patients, indicating 
that  alloHSCT  might  have  curative  potential  in 
patients with del 17p. 
The  final  results  of  the  prospective  GCLLSG 
CLL3X  trial  on  the  feasibility  and  efficacy  of  RIC 
alloHSCT in patients with poor-risk CLL were recent-
ly published [70]. After a median follow-up of 46 
months (7-102 months), 4-year non-relapse mortal-
ity (NRM), EFS, and OS were 23%, 42%, and 65%, 
respectively. Among the 52 patients for whom MRD 
monitoring  results  were  available,  27  (52%)  were 
alive and MRD negative 12 months after transplanta-
tion.  EFS  was  similar  in  all  genetic  subgroups, 
including patients with del 17p. Multivariate analysis 
showed  that  uncontrolled  disease  at  the  time  of 
alloHSCT and in vivo T-cell depletion with alemtu-
zumab, but no del 17p, previous purine analogue 
refractoriness, and donor source (human leukocyte 
antigen-identical siblings or unrelated donors) had 
an adverse impact on EFS and OS, indicating that 
alloHSCT can result in long-term MRD-negative sur-
vival in up to 50% of patients, independent of the 
underlying genomic risk profile. A recent update of 
the CLL3X data with work-up of TP53 mutation sta-
tus showed that the adverse impact of TP53 muta-
tion,  similarly  as  del  17p,  can  be  overcome  by 
alloHSCT [71]. 
Although controlled trials are lacking, currently 
available data strongly suggest that alloHSCT is the 
only therapy with curative potential in high-risk CLL. 
In contrast to conventional immunochemotherapy, 
it  can  provide  long-term  disease  control,  even  in 
patients with del 17p or other unfavorable biological 
and clinical risk factors. 
Conclusions
Substantial progress has been made in the under-
standing  and  treatment  of  CLL,  and  advances  in 
Table 3. Results of prospective clinical trials on reduced-intensity conditioning (RIC) alloHSCT in CLL
  Schetelig   Sorror  Khouri  Brown  Delgado  Dreger
  et al. (61)  et al. (67)  et al. (65)  et al. (66)  et al. (68)  et al. (70)
Number of patients  30  82  39  46  41  90
Conditioning regimen  FB/ATGa  F/TBI2b  FCR +/– ATGc  FBd  FM/CD52e  F/C +/–ATGf
Proportion of alternative donorsg  57%  37%  18%  67%  41%  60%
4-year PFS  58%  39% (5y)  44%  34% (2y)  45% (2y)  42%
4-year OS  69%  50% (5y)  48%  54% (2y)  51% (2y)  65%
4-year NRM  15%  23% (5y)  n.r.  17% (2y)  26% (2y)  23%
Extensive chronic GVHD  21%  49-53%  58%  38%  5%  14%
Median follow-up [years] (range)  3.7 (2.1-5.6)  5  2.3 (.3-6.7)  1.7  1.3 (0-5.2)  3.8 (0.6-8.5)
aFludarabine, busulfan, anti-thymocyte globulin (ATG)
bFludarabine, total body irradiation 2Gy
cFludarabine, cyclophosphamide, rituximab plus ATG in alternative donor transplants
dFludarabine, busulfan
eFludarabine, melphalan, alemtuzumab
fFludarabine, cyclophosphamide plus ATG in alternative donor transplants
gDonor other than HLA-identical siblings
NRM: non-relapse mortality, GVHD: graft-versus-host disease
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physicians to better predict patient risk profiles and 
response to therapy. Several studies have validated 
the components and impact of poor-risk CLL, and 
international  guidelines  have  implemented  these 
criteria in their treatment recommendations. As a 
result, Poor-risk patients can now be identified with 
greater accuracy and offered intensified treatment 
options,  such  as  allo  HSCT  or  alemtuzumab. 
Depending on patient performance status, personal 
preference, and the availability of a stem cell donor, 
these treatment options offer a tailored treatment 
approach, providing an opportunity to cure CLL in 
this poor-risk population. 
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